Vis enkel innførsel

dc.contributor.authorVolokhina, Elena B.
dc.contributor.authorvan de Kar, Nicole C.A.J.
dc.contributor.authorBergseth, Grethe
dc.contributor.authorvan der Velden, Thea J.A.M.
dc.contributor.authorWestra, Dineke
dc.contributor.authorWetzels, Jack F.M.
dc.contributor.authorvan den Heuvel, Lambertus P.
dc.contributor.authorMollnes, Tom Eirik
dc.date.accessioned2016-03-17T09:24:17Z
dc.date.available2016-03-17T09:24:17Z
dc.date.issued2015-06-23
dc.description.abstractComplement C5 inhibitor eculizumab treatment in atypical hemolytic uremic syndrome is effective, but associated with high costs. Complement inhibition monitoring in these patients has not been standardized. In this study we evaluated novel functional assays for application in routine follow-up. We documented that the Wieslab® complement screen assay showed a sensitivity of 1–2% of C5 activity by adding purified C5 or normal human serum to a C5 deficient serum. All the patient samples obtained during the treatment course, were completely blocked for terminal complement pathway activity for up to four weeks after the eculizumab infusion. Levels of complexes between eculizumab and C5 were inversely correlated to the complement activity (p = 0.01). Moreover, titrating serum from eculizumab-treated patients into normal serum revealed that eculizumab was present in excess up to four weeks after infusion. Thus, we demonstrate sensitive, reliable and easy-performed assays which can be used to design individual eculizumab dosage regimens.en_US
dc.descriptionPublished version also available at <a href=http://dx.doi.org/10.1016/j.clim.2015.05.018>http://dx.doi.org/10.1016/j.clim.2015.05.018</a>en_US
dc.identifier.citationClinical Immunology 2015, 160(2):237-243en_US
dc.identifier.cristinIDFRIDAID 1278145
dc.identifier.doi10.1016/j.clim.2015.05.018
dc.identifier.issn1521-7035
dc.identifier.urihttps://hdl.handle.net/10037/8996
dc.identifier.urnURN:NBN:no-uit_munin_8576
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.relation.projectIDNorges forskningsråd: 223255en_US
dc.rights.accessRightsopenAccess
dc.subjectHemolytic uremic syndromeen_US
dc.subjectComplementen_US
dc.subjectEculizumaben_US
dc.subjectPersonalized therapyen_US
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750en_US
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750en_US
dc.titleSensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndromeen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel